We serve Chemical Name:N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide CAS:606111-20-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide](https://a.dearchem.com/CAS2/606111-20-0.png)
Chemical Name:N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide
CAS.NO:606111-20-0
Synonyms:N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide
Molecular Formula:C19H26N4O2S
Molecular Weight:374.50000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:96.02000
Exact Mass:374.17800
LogP:3.44370
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide Use and application,N-Isopropyl-2-(2-{[2-oxo-2-(1-piperidinyl)ethyl]sulfanyl}-1H-benz imidazol-1-yl)acetamide technical grade,usp/ep/jp grade.
Related News: A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 2-acetamido-N,3-dimethylpentanamide manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Acetic acid (2S,3R,4R,5S,6S)-4,5-diacetoxy-2-[(2S,3R,4R,5S,6S)-2-((2R,3R,4R,5S,6S)-3-allyloxy-5-benzyloxy-2-methoxy-6-methyl-tetrahydro-pyran-4-yloxy)-5-benzyloxy-4-methoxy-6-methyl-tetrahydro-pyran-3-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester suppliers In the US, however, ODAC in April voted to keep alive the accelerated approval for Tecentriq plus Abraxane (nab-paclitaxel) in mTNBC while additional confirmatory trials are ongoing. Thiocumarin-3-carbonsaeure-(4-chloranilid) vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Acetic acid (2S,3R,4R,5S,6S)-4,5-diacetoxy-2-[(2S,3R,4R,5S,6S)-2-((2R,3R,4R,5S,6S)-3-allyloxy-5-benzyloxy-2-methoxy-6-methyl-tetrahydro-pyran-4-yloxy)-5-benzyloxy-4-methoxy-6-methyl-tetrahydro-pyran-3-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester suppliers In the US, however, ODAC in April voted to keep alive the accelerated approval for Tecentriq plus Abraxane (nab-paclitaxel) in mTNBC while additional confirmatory trials are ongoing. Thiocumarin-3-carbonsaeure-(4-chloranilid) vendor & factory.
